New Stock News | Tumor drug manufacturer Deshengji Medicine plans to list in Hong Kong with a target fundraising amount of $200 million.

According to reports, Deshengji Pharmaceuticals, which is developing cancer treatment drugs, is planning to go public in Hong Kong with a target fundraising of $200 million. They are currently in discussions with investment banks regarding the matter. Deshengji Pharmaceuticals has developed a new generation of anti-cancer drugs, which have shown preliminary evidence of significantly inhibiting solid tumors triggered by specific gene mutations, including non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Information shows that Deshengji Pharmaceuticals completed a $108 million Series B financing in December last year, with participation from IDG Capital, Matrix Partners, WuXi AppTec Venture Fund, Temasek, Sequoia China, and Medicxi. It is understood that Boyu Capital is also a shareholder. The funds raised in Deshengji's Series B financing will be used to support the Phase III pivotal clinical trial of the core candidate drug elisrasib (D3S-001), evaluating its application as a monotherapy and in combination therapy in patients with KRAS G12C mutations in the United States, China, and the European Union among other regions, to advance global regulatory submissions.